Stocklytics Platform
Asset logo for symbol SHPH
Shuttle Pharmaceuticals Holdings
SHPH40
$0.94arrow_drop_down5.11%-$0.05
Penny Stock
Asset logo for symbol SHPH
SHPH40

$0.94

arrow_drop_down5.11%

Performance History

Chart placeholder
Key Stats
Open$1.06
Prev. Close$1.07
EPS-3.51
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.33M
PE Ratio-
LOWHIGH
Day Range0.96
1.11
52 Week Range0.96
5.35
Ratios
Revenue-
EBITDA Margin %-
EPS-3.51

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Shuttle Pharmaceuticals Holdings (SHPH)

Shuttle Pharmaceuticals Holdings Inc (SHPH) is a pharmaceutical company that specializes in the research, development, and commercialization of innovative drugs. With a strong focus on improving patient outcomes and addressing unmet medical needs, SHPH has established itself as a leader in the industry. The company's stock price history reflects its consistent growth and investor confidence. Over the past several years, SHPH's stock price has steadily increased, demonstrating the market's recognition of its value. This upward trajectory is a testament to SHPH's strong business fundamentals and promising pipeline of drug candidates.
As of the latest quote, SHPH's stock is trading at a favorable price, making it an attractive investment opportunity. The company's impressive portfolio and commitment to excellence have garnered the attention of industry experts, resulting in positive stock news coverage. Analysts have praised SHPH for its strategic acquisitions, partnerships, and successful clinical trials. These developments have significantly contributed to SHPH's market capitalization, which currently stands at a substantial figure.
Websitecall_made
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
CEO
Dr. Anatoly Dritschilo M.D.
Headquarters
Rockville
Employees
7
Exchange
NASDAQ
add Shuttle Pharmaceuticals Holdings to watchlist

Keep an eye on Shuttle Pharmaceuticals Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Shuttle Pharmaceuticals Holdings 's (SHPH) price per share?

The current price per share for Shuttle Pharmaceuticals Holdings (SHPH) is $0.95. The stock has seen a price change of -$0.05 recently, indicating a -5.12% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Shuttle Pharmaceuticals Holdings (SHPH)?

For Shuttle Pharmaceuticals Holdings (SHPH), the 52-week high is $5.35, which is 465.75% from the current price. The 52-week low is $0.93, the current price is 2.05% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Shuttle Pharmaceuticals Holdings (SHPH) a growth stock?

Shuttle Pharmaceuticals Holdings (SHPH) has shown an average price growth of -6.8% over the past three years. It has received a score of 70 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Shuttle Pharmaceuticals Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Shuttle Pharmaceuticals Holdings (SHPH) stock price performance year to date (YTD)?

As of the latest data, Shuttle Pharmaceuticals Holdings (SHPH) has a year-to-date price change of -76.56%. Over the past month, the stock has experienced a price change of -21.82%. Over the last three months, the change has been -53.63%. Over the past six months, the figure is -70.47%.
help

Is Shuttle Pharmaceuticals Holdings (SHPH) a profitable company?

Shuttle Pharmaceuticals Holdings (SHPH) has a net income of -$6.59M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$5.89M. Furthermore, the EBITDA is -$5.74M.
help

What is the market capitalization of Shuttle Pharmaceuticals Holdings (SHPH)?

Shuttle Pharmaceuticals Holdings (SHPH) has a market capitalization of $3.33M. The average daily trading volume is 0.99, indicating the stock's liquidity and investor engagement.

News

Shuttle Pharma Provides Third Quarter 2024 Corporate Update
SHUTTLE PHARMACEUTICALS
ROPIDOXURIDINE
GLIOBLASTOMA
PHASE 2 CLINICAL TRIAL
FUNDING
Nov 13, 2024

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
SHUTTLE PHARMACEUTICALS
PUBLIC OFFERING
CLINICAL TRIALS
Oct 30, 2024

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
SHUTTLE PHARMACEUTICALS HOLDINGS
PUBLIC OFFERING
CLINICAL TRIALS
Oct 30, 2024

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
SHUTTLE PHARMACEUTICALS
ROPIDOXURIDINE
GLIOBLASTOMA
CLINICAL TRIAL
Sep 16, 2024

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma reports progress in breast cancer treatment By Investing.com - Investing.com Canada
SHUTTLE PHARMACEUTICALS
BREAST CANCER
SP-1-303
RADIATION THERAPY
Jul 20, 2024

Shuttle Pharma reports progress in breast cancer treatment By Investing.com - Investing.com Canada

Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE - GlobeNewswire
HDAC INHIBITOR
ATM ACTIVATION
ER EXPRESSION
BREAST CANCER
RADIATION THERAPY
Jul 19, 2024

Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE - GlobeNewswire

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level